MYO7A_HUMAN,N2173S,0.492,-,-,-
MYO7A_HUMAN,L2174C,0.912,Loss of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,L2174G,0.945,Altered Stability (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), PS00008,-
MYO7A_HUMAN,V2175L,0.734,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000336,-
MYO7A_HUMAN,E2183G,0.863,Loss of Strand (Pr = 0.26 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000336|PS00008,-
MYO7A_HUMAN,M2190L,0.576,, ELME000045|ELME000148|ELME000317,-
MYO7A_HUMAN,D2192H,0.778,Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000053|ELME000148|ELME000317,-
MYO7A_HUMAN,L2194I,0.285,-,-,-
MYO7A_HUMAN,T2195E,0.751,Altered Disordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,Y2197F,0.519,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,S2206N,0.237,-,-,-
MYO7A_HUMAN,K2207Q,0.491,-,-,-
MYO7A_HUMAN,K2207S,0.649,Altered Disordered interface (Pr = 0.38 | P = 8.0e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.04); Loss of Helix (Pr = 0.27 | P = 0.04); Altered DNA binding (Pr = 0.25 | P = 8.9e-03); Loss of Ubiquitylation at K2207 (Pr = 0.16 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000053|ELME000202|ELME000239|PS00005,-
MYO7A_HUMAN,G2214D,0.286,-,-,-
MYO7A_HUMAN,K2215R,0.062,-,-,-
MYO7A_HUMAN,K2215S,0.149,-,-,-
MYO7A_HUMAN,P541L,0.776,Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of GPI-anchor amidation at N543 (Pr = 0.01 | P = 0.03), ELME000081|ELME000083|ELME000120|ELME000182,-
MYO7A_HUMAN,C652R,0.954,Loss of Allosteric site at R657 (Pr = 0.32 | P = 2.9e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Disordered interface (Pr = 0.22 | P = 0.02); Loss of Catalytic site at R657 (Pr = 0.19 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000012|ELME000106|ELME000313,-
MYO7A_HUMAN,Q493P,0.941,Altered Metal binding (Pr = 0.34 | P = 2.3e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Allosteric site at F489 (Pr = 0.29 | P = 2.3e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Loss of Catalytic site at N492 (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,A1628S,0.165,-,-,-
MYO7A_HUMAN,T1639M,0.310,-,-,-
MYO7A_HUMAN,M599I,0.262,-,-,-
MYO7A_HUMAN,L452P,0.944,Altered Coiled coil (Pr = 0.38 | P = 0.01); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Allosteric site at F449 (Pr = 0.26 | P = 7.3e-03), None,-
MYO7A_HUMAN,R756W,0.863,Altered DNA binding (Pr = 0.41 | P = 3.0e-04); Loss of Acetylation at K753 (Pr = 0.24 | P = 0.02); Altered Disordered interface (Pr = 0.22 | P = 0.03), ELME000134|ELME000137|ELME000146,-
MYO7A_HUMAN,R1240W,0.823,Altered Ordered interface (Pr = 0.39 | P = 1.1e-03); Gain of N-linked glycosylation at N1237 (Pr = 0.04 | P = 0.02), ELME000053|ELME000070|ELME000202|PS00001,-
MYO7A_HUMAN,A1251P,0.924,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.04), ELME000239|ELME000336,-
MYO7A_HUMAN,G1782A,0.844,Loss of Allosteric site at Y1780 (Pr = 0.24 | P = 0.02); Loss of Acetylation at K1779 (Pr = 0.19 | P = 0.05); Gain of Ubiquitylation at K1787 (Pr = 0.16 | P = 0.03); Gain of Proteolytic cleavage at D1783 (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,L1027P,0.898,Altered Stability (Pr = 0.38 | P = 3.3e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Loss of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,R668C,0.922,Altered Ordered interface (Pr = 0.40 | P = 1.4e-03); Altered Metal binding (Pr = 0.29 | P = 4.9e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Allosteric site at E663 (Pr = 0.23 | P = 0.02); Loss of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000012|ELME000052|ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,L1154P,0.963,Altered Stability (Pr = 0.34 | P = 4.2e-03); Loss of Helix (Pr = 0.28 | P = 0.02), ELME000137|ELME000313,-
MYO7A_HUMAN,I665V,0.704,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Allosteric site at E663 (Pr = 0.22 | P = 0.03); Gain of ADP-ribosylation at R669 (Pr = 0.19 | P = 0.05); Altered Disordered interface (Pr = 0.16 | P = 0.04), ELME000012|ELME000052|PS00005|PS00008,-
MYO7A_HUMAN,R675C,0.896,Altered Ordered interface (Pr = 0.42 | P = 6.9e-04); Loss of Allosteric site at R675 (Pr = 0.36 | P = 1.1e-03); Altered DNA binding (Pr = 0.26 | P = 7.0e-03); Altered Metal binding (Pr = 0.10 | P = 0.05); Loss of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000020|ELME000062|ELME000064,-
MYO7A_HUMAN,R1873Q,0.776,Altered Metal binding (Pr = 0.24 | P = 0.04); Loss of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered Coiled coil (Pr = 0.17 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.04), ELME000134|ELME000313,-
MYO7A_HUMAN,L237R,0.963,Altered Metal binding (Pr = 0.29 | P = 5.0e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Allosteric site at R241 (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.14 | P = 0.02); Loss of Catalytic site at E238 (Pr = 0.09 | P = 0.05), ELME000182|ELME000336,-
MYO7A_HUMAN,G519D,0.821,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03), PS00008,-
MYO7A_HUMAN,G1982E,0.860,Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.21 | P = 4.1e-03); Loss of Proteolytic cleavage at D1981 (Pr = 0.11 | P = 0.04), ELME000002|PS00008,-
MYO7A_HUMAN,A771S,0.379,-,-,-
MYO7A_HUMAN,G1159S,0.819,, ELME000313|ELME000336,-
MYO7A_HUMAN,R1873W,0.795,Altered Metal binding (Pr = 0.22 | P = 0.05); Loss of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,R206C,0.917,Altered Disordered interface (Pr = 0.51 | P = 8.8e-04); Loss of Relative solvent accessibility (Pr = 0.40 | P = 7.5e-04); Altered DNA binding (Pr = 0.39 | P = 4.2e-04); Altered Metal binding (Pr = 0.29 | P = 3.9e-03); Gain of Allosteric site at N201 (Pr = 0.26 | P = 9.1e-03); Loss of Methylation at K203 (Pr = 0.26 | P = 1.4e-03); Loss of Catalytic site at R206 (Pr = 0.24 | P = 6.6e-03); Altered Transmembrane protein (Pr = 0.20 | P = 5.1e-03); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03); Loss of GPI-anchor amidation at N201 (Pr = 0.01 | P = 0.03), PS00005,-
MYO7A_HUMAN,A1224T,0.577,Altered Metal binding (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000136|ELME000159|ELME000182|ELME000292,-
MYO7A_HUMAN,P1244R,0.807,Altered Disordered interface (Pr = 0.19 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000053|ELME000064|ELME000202,-
MYO7A_HUMAN,R241S,0.939,Loss of Allosteric site at R241 (Pr = 0.37 | P = 9.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered DNA binding (Pr = 0.26 | P = 4.6e-03); Altered Metal binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at E238 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.07 | P = 0.02), ELME000336,-
MYO7A_HUMAN,L326P,0.975,Altered Metal binding (Pr = 0.34 | P = 0.01); Gain of Allosteric site at N330 (Pr = 0.29 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Catalytic site at H327 (Pr = 0.21 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000193,-
MYO7A_HUMAN,L1937P,0.937,Altered Stability (Pr = 0.15 | P = 0.02), ELME000052|ELME000053|ELME000106|ELME000146|ELME000239|ELME000313,-
MYO7A_HUMAN,K164R,0.733,Loss of Methylation at K164 (Pr = 0.29 | P = 7.1e-04); Loss of Catalytic site at E159 (Pr = 0.28 | P = 2.7e-03); Altered Metal binding (Pr = 0.27 | P = 9.1e-03); Gain of Allosteric site at E159 (Pr = 0.22 | P = 0.03), PS00008|PS00017,-
MYO7A_HUMAN,M283T,0.807,Gain of Relative solvent accessibility (Pr = 0.33 | P = 3.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.04); Gain of Disulfide linkage at C286 (Pr = 0.16 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Sulfation at Y278 (Pr = 0.02 | P = 0.04), ELME000182,-
MYO7A_HUMAN,D365N,0.182,-,-,-
MYO7A_HUMAN,T193P,0.851,Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Allosteric site at E197 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.7e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000052|ELME000136|ELME000159|ELME000292,-
MYO7A_HUMAN,P132L,0.913,Altered Ordered interface (Pr = 0.42 | P = 7.3e-04); Altered Metal binding (Pr = 0.37 | P = 1.9e-03); Loss of Allosteric site at F135 (Pr = 0.32 | P = 2.7e-03); Gain of Helix (Pr = 0.30 | P = 8.3e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058|ELME000233,-
MYO7A_HUMAN,Y2015H,0.881,Altered Metal binding (Pr = 0.38 | P = 2.8e-03); Altered Ordered interface (Pr = 0.34 | P = 6.7e-03); Loss of Allosteric site at Y2015 (Pr = 0.27 | P = 9.1e-03); Gain of Catalytic site at Y2015 (Pr = 0.15 | P = 0.02); Loss of Sulfation at Y2016 (Pr = 0.02 | P = 0.03), None,-
MYO7A_HUMAN,E1641K,0.628,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), PS00005,-
MYO7A_HUMAN,S1605Y,0.891,Altered Ordered interface (Pr = 0.27 | P = 7.5e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R1604 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000008|ELME000100|ELME000108|ELME000120|ELME000233|ELME000271|ELME000278|PS00004,-
MYO7A_HUMAN,R244P,0.887,Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Allosteric site at R241 (Pr = 0.31 | P = 1.3e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Catalytic site at R241 (Pr = 0.09 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|ELME000259|PS00007,-
MYO7A_HUMAN,R668H,0.862,Altered Ordered interface (Pr = 0.37 | P = 3.0e-03); Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.01); Gain of Allosteric site at Y672 (Pr = 0.19 | P = 0.05); Gain of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000012|ELME000052|ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,G2137E,0.917,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000147|ELME000335,-
MYO7A_HUMAN,T204A,0.742,Altered Disordered interface (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.26 | P = 7.0e-03); Loss of Allosteric site at F199 (Pr = 0.26 | P = 0.01); Gain of Methylation at K203 (Pr = 0.25 | P = 9.5e-04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of Catalytic site at N201 (Pr = 0.22 | P = 9.2e-03); Gain of Ubiquitylation at K203 (Pr = 0.15 | P = 0.04); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03); Loss of GPI-anchor amidation at N201 (Pr = 0.01 | P = 0.03), PS00005|PS00008,-
MYO7A_HUMAN,R90P,0.875,Altered Ordered interface (Pr = 0.30 | P = 4.6e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Allosteric site at Y89 (Pr = 0.23 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 7.7e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), PS00007,-
MYO7A_HUMAN,S1530L,0.421,-,-,-
MYO7A_HUMAN,V679I,0.152,-,-,-
MYO7A_HUMAN,D2142N,0.349,-,-,-
MYO7A_HUMAN,M1W,0.977,Loss of Intrinsic disorder (Pr = 0.52 | P = 5.2e-03); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000355,-
MYO7A_HUMAN,V2A,0.889,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.23 | P = 6.3e-04); Altered Metal binding (Pr = 0.04 | P = 0.04), ELME000285,-
MYO7A_HUMAN,V2P,0.932,Gain of Intrinsic disorder (Pr = 0.42 | P = 6.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.4e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,V2Y,0.920,Gain of Strand (Pr = 0.27 | P = 0.03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 6.7e-04); Altered Metal binding (Pr = 0.04 | P = 0.04); Gain of Sulfation at V2 (Pr = 0.02 | P = 0.03), ELME000163|ELME000182|ELME000355,-
MYO7A_HUMAN,I3L,0.536,Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of N-terminal acetylation at M1 (Pr = 0.27 | P = 1.8e-04), None,-
MYO7A_HUMAN,I3S,0.902,Gain of Intrinsic disorder (Pr = 0.59 | P = 4.5e-04); Altered Metal binding (Pr = 0.27 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.5e-04); Altered Stability (Pr = 0.17 | P = 0.02), None,-
MYO7A_HUMAN,Q5P,0.907,Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of N-terminal acetylation at M1 (Pr = 0.19 | P = 7.0e-04); Altered Stability (Pr = 0.19 | P = 0.01), None,-
MYO7A_HUMAN,R15K,0.135,-,-,-
MYO7A_HUMAN,E45D,0.207,-,-,-
MYO7A_HUMAN,K125R,0.363,-,-,-
MYO7A_HUMAN,N148H,0.541,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000008|ELME000062|ELME000100|ELME000108|PS00004,-
MYO7A_HUMAN,N148S,0.386,-,-,-
MYO7A_HUMAN,S149I,0.548,Altered Ordered interface (Pr = 0.33 | P = 6.8e-03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Metal binding (Pr = 0.22 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000008|ELME000062|PS00004,-
MYO7A_HUMAN,I217V,0.452,-,-,-
MYO7A_HUMAN,L247S,0.503,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at R250 (Pr = 0.27 | P = 0.01); Altered Stability (Pr = 0.11 | P = 0.03); Altered Metal binding (Pr = 0.06 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|PS00007,-
MYO7A_HUMAN,L247T,0.424,-,-,-
MYO7A_HUMAN,Y256H,0.892,Altered Metal binding (Pr = 0.52 | P = 1.1e-03); Loss of Allosteric site at Y256 (Pr = 0.30 | P = 4.1e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04), ELME000020|ELME000120|ELME000182,-
MYO7A_HUMAN,L259S,0.921,Altered Ordered interface (Pr = 0.34 | P = 5.6e-03); Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.29 | P = 3.1e-03); Gain of Catalytic site at Y256 (Pr = 0.13 | P = 0.03); Altered Metal binding (Pr = 0.09 | P = 0.01), ELME000020|ELME000053|ELME000120|ELME000182,-
MYO7A_HUMAN,D265A,0.303,-,-,-
MYO7A_HUMAN,L270I,0.338,-,-,-
MYO7A_HUMAN,Q274H,0.087,-,-,-
MYO7A_HUMAN,N285S,0.378,-,-,-
MYO7A_HUMAN,T288V,0.246,-,-,-
MYO7A_HUMAN,E290D,0.240,-,-,-
MYO7A_HUMAN,A353T,0.099,-,-,-
MYO7A_HUMAN,P363S,0.131,-,-,-
MYO7A_HUMAN,P364Q,0.112,-,-,-
MYO7A_HUMAN,S368G,0.179,-,-,-
MYO7A_HUMAN,R373H,0.655,Altered Stability (Pr = 0.13 | P = 0.03), ELME000063|ELME000106|PS00005,-
MYO7A_HUMAN,L375I,0.245,-,-,-
MYO7A_HUMAN,E389D,0.253,-,-,-
MYO7A_HUMAN,D425E,0.048,-,-,-
MYO7A_HUMAN,V426T,0.115,-,-,-
MYO7A_HUMAN,K427E,0.240,-,-,-
MYO7A_HUMAN,K427N,0.208,-,-,-
MYO7A_HUMAN,K427R,0.117,-,-,-
MYO7A_HUMAN,S429P,0.361,-,-,-
MYO7A_HUMAN,F456L,0.802,Altered Coiled coil (Pr = 0.34 | P = 8.9e-03); Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04), None,-
